PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail of cancer drugs targets brain metastases in melanoma patients
Disease control OngoingThis Phase 2 trial tests whether combining bevacizumab (Avastin) with atezolizumab (Tecentriq), with or without cobimetinib (Cotellic), can shrink or control melanoma that has spread to the brain. The study enrolls 29 adults with untreated brain metastases who are not taking ster…
Matched conditions: PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
PET scans may let melanoma patients stop treatment sooner
Disease control OngoingThis study looks at whether doctors can safely stop standard anti-PD-1 immunotherapy early in people with advanced melanoma that cannot be surgically removed. By using PET/CT scans and tumor biopsies as guides, the goal is to reduce treatment side effects and burden without harmi…
Matched conditions: PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kidney transplant patients with cancer: drug combo aims to fight tumors without losing the donated kidney
Disease control OngoingThis early-stage study tests whether a mix of three drugs—tacrolimus, nivolumab, and ipilimumab—can shrink or control certain skin cancers in people who have had a kidney transplant. The main goal is to see if the cancer responds without causing the body to reject the transplante…
Matched conditions: PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a rheumatoid arthritis drug tame Immunotherapy's side effects?
Disease control OngoingThis study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…
Matched conditions: PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Zapping brain tumors without zapping memory: new trial for melanoma patients
Disease control OngoingThis phase II trial is testing whether a precise, high-dose radiation treatment called stereotactic radiosurgery can control melanoma that has spread to more than three spots in the brain. The study includes 49 patients and also checks whether this approach helps preserve memory …
Matched conditions: PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Fiber fix: diet study hopes to boost cancer immunotherapy
Knowledge-focused OngoingThis study looks at whether eating a high-fiber diet can change the gut bacteria of people with advanced melanoma who are receiving standard immunotherapy. About 50 participants will be randomly assigned to either a high-fiber or a healthy control diet for a set period. The main …
Matched conditions: PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC